Title: Depression, IV: STAR*D Treatment Trial for Depression
Abstract: Back to table of contents Previous article Next article Images in NeuroscienceFull AccessDepression, IV: STAR*D Treatment Trial for DepressionA. John Rush, M.D., Madhukar Trivedi, M.D., , and Maurizio Fava, M.D., A. John Rush, M.D., Madhukar Trivedi, M.D., Dallas, Tex., and Maurizio Fava, M.D., Boston, Mass.Published Online:1 Feb 2003https://doi.org/10.1176/appi.ajp.160.2.237AboutSectionsPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinked InEmail Major depressive disorder is a common, costly, and disabling condition affecting 4.9%–17.9% of the population in a lifetime. From 20%–30% of affected persons suffer a chronic, relapsing course. Many medications and several time-limited psychotherapies have shown established efficacy in randomized controlled trials. Among outpatients with major depressive disorder treated for the first time, about 50% will have a response (i.e., exhibit a clinically significant symptom reduction). However, of these "responders," only 50%–70% will achieve symptom remission, which, since remission is associated with the best day-to-day functioning and best prognosis, is the goal of treatment.For those cases of depression not remitting with the first treatment, little controlled trial evidence is available by which to select the next treatment. It is believed that a switch to a new, second treatment may result in a 50% response rate, with lower response rates expected with the third or fourth treatment step. Psychiatry faces the challenge of recommending the next best treatment steps, or series of steps, for depressed persons not experiencing a remission with the first or subsequent treatments. Therapeutic strategies may include switching (i.e., stopping one treatment and starting another) or augmenting/combining (i.e., adding a second treatment to the first).STAR*D (Sequenced Treatment Alternatives to Relieve Depression) is a multisite, prospective, sequentially randomized controlled trial of outpatients with nonpsychotic major depressive disorder that is using randomization to compare various switching or augmenting strategies (as shown in the Figure) either commonly used or that are based on pharmacologic reasoning. The study includes self-declared patients seeking treatment at either primary or specialty care practices.Patients, as in practice, may select among the strategies. For instance, a patient may choose to only accept augmentation or only switching. However, all participants are randomly assigned to the specific treatments within the strategies that they find acceptable. This so-called equipoise stratified randomized design mimics clinical practice, so that results should have high practical relevance.Response, remission, daily functioning, and service cost/utilization will be objectively assessed. Results, expected in the year 2006, will determine whether there is a preferred next step for varying types and degrees of treatment-resistant depression.Address reprint requests to Dr. Tamminga, Department of Psychiatry, University of Texas Southwestern Medical Center, 5323 Harry Hines Blvd., Dallas, TX 75390. STAR*D (Sequenced Treatment Alternatives to Relieve Depression) FiguresReferencesCited byDetailsCited ByOccurrence of Side Effects in Treatment-Resistant Depression: Role of Clinical, Socio-Demographic and Environmental Characteristics6 December 2021 | Frontiers in Psychiatry, Vol. 12Magnetic Resonance Imaging Studies on Acupuncture Therapy in Depression: A Systematic Review20 August 2021 | Frontiers in Psychiatry, Vol. 12DASH and Mediterranean-Dash Intervention for Neurodegenerative Delay (MIND) Diets Are Associated With Fewer Depressive Symptoms Over Time21 February 2020 | The Journals of Gerontology: Series A, Vol. 76, No. 1Pharmacological Augmentation in Unipolar Depression: A Guide to the Guidelines13 May 2020 | International Journal of Neuropsychopharmacology, Vol. 23, No. 9Outcome of First-admission Depression Treated in a Specialized Mood Disorders Service1 November 2020 | Journal of Psychiatric Practice, Vol. 26, No. 6Stimulation du nerf vague dans le traitement de la dépressionLa Presse Médicale, Vol. 48, No. 12Neuroimaging Biomarkers at Baseline Predict Electroconvulsive Therapy Overall Clinical Response in Depression9 January 2019 | The Journal of ECT, Vol. 35, No. 2Cell-type-specific role for nucleus accumbens neuroligin-2 in depression and stress susceptibility16 January 2018 | Proceedings of the National Academy of Sciences, Vol. 115, No. 5Association of Novel ALX4 Gene Polymorphisms with Antidepressant Treatment Response: Findings from the CO-MED Trial3 May 2018 | Complex Psychiatry, Vol. 4, No. 1Alcohol Use Disorder as a Possible Predictor of Electroconvulsive Therapy ResponseThe Journal of ECT, Vol. 33, No. 2Time-varying SMART design and data analysis methods for evaluating adaptive intervention effects30 August 2016 | BMC Medical Research Methodology, Vol. 16, No. 1, Vol. 30Combination Strategies in Treatment-Resistant Depression18 November 2016Biological Psychiatry, Vol. 79, No. 4L'Encéphale, Vol. 42, No. 1European Neuropsychopharmacology, Vol. 26, No. 3Journal of Affective Disorders, Vol. 205NeuroImage: Clinical, Vol. 12Circadian dysregulation of clock genes: clues to rapid treatments in major depressive disorder4 November 2014 | Molecular Psychiatry, Vol. 20, No. 1Journal of the American Statistical Association, Vol. 110, No. 510Genetic Determinants of DepressionHarvard Review of Psychiatry, Vol. 23, No. 1Psychological Medicine, Vol. 44, No. 4Translational Psychiatry, Vol. 4, No. 4BMC Psychiatry, Vol. 14, No. 1PLoS ONE, Vol. 9, No. 5Neuropsychiatry, Vol. 4, No. 1The World Journal of Biological Psychiatry, Vol. 15, No. 2The Antidepressant-like Effect of Physical Activity on a Voluntary Running WheelMedicine & Science in Sports & Exercise, Vol. 45, No. 5Journal of Psychiatric Research, Vol. 47, No. 9Psychopharm Review, Vol. 48, No. 12The drugs don't work? antidepressants and the current and future pharmacological management of depression30 April 2012 | Therapeutic Advances in Psychopharmacology, Vol. 2, No. 5The 5-HT deficiency theory of depression: perspectives from a naturalistic 5-HT deficiency model, the tryptophan hydroxylase 2 Arg 439 His knockin mouse5 September 2012 | Philosophical Transactions of the Royal Society B: Biological Sciences, Vol. 367, No. 1601Computer analysis of the structure – antidepressant activity relationship in series of 1,2,4-triazole and thietane-1,1-dioxide derivatives18 August 2012 | Pharmaceutical Chemistry Journal, Vol. 46, No. 4Adherence to guidelines and effectiveness of inpatient treatment for unipolar depression5 December 2011 | International Journal of Psychiatry in Clinical Practice, Vol. 16, No. 2Usefulness of Symptom Feedback to Providers in an Integrated Primary Care-Mental Health Care ClinicLisa Zubkoff, Ph.D., Yinong Young-Xu, Sc.D., Brian Shiner, M.D., M.P.H., Andy Pomerantz, M.D., and Bradley V. Watts, M.D., M.P.H.1 January 2012 | Psychiatric Services, Vol. 63, No. 1European Archives of Psychiatry and Clinical Neuroscience, Vol. 262, No. 1Revista Colombiana de Psiquiatría, Vol. 41, No. 4Contemporary Clinical Trials, Vol. 33, No. 1Child and Adolescent Psychiatric Clinics of North America, Vol. 21, No. 3European Journal of Pharmacology, Vol. 679, No. 1-3Journal of Ethnopharmacology, Vol. 143, No. 2The International Journal of Neuropsychopharmacology, Vol. 15, No. 05Children of Depressed Mothers 1 Year After Remission of Maternal Depression: Findings From the STAR*D-Child StudyPriya Wickramaratne, Ph.D., Marc J. Gameroff, Ph.D., Daniel J. Pilowsky, M.D., M.P.H., Carroll W. Hughes, Ph.D., Judy Garber, Ph.D., Erin Malloy, M.D., Cheryl King, Ph.D., Gabrielle Cerda, M.D., A. Bela Sood, M.D., Jonathan E. Alpert, M.D., Ph.D., Madhukar H. Trivedi, M.D., Maurizio Fava, M.D., A. John Rush, M.D., Stephen Wisniewski, Ph.D., and Myrna M. Weissman, Ph.D.1 June 2011 | American Journal of Psychiatry, Vol. 168, No. 6European Archives of Psychiatry and Clinical Neuroscience, Vol. 261, No. S3Journal of Ethnopharmacology, Vol. 137, No. 1Molecular Psychiatry, Vol. 16, No. 12Klinik Psikofarmakoloji Bülteni-Bulletin of Clinical Psychopharmacology, Vol. 21, No. sup1PLoS ONE, Vol. 6, No. 8A pooled analysis of two randomised, placebo-controlled studies of extended release quetiapine fumarate adjunctive to antidepressant therapy in patients with major depressive disorderJournal of Affective Disorders, Vol. 127, No. 1-3Comparisons of the Efficacy and Tolerability of Extended-Release Venlafaxine, Mirtazapine, and Paroxetine in Treatment-Resistant DepressionJournal of Clinical Psychopharmacology, Vol. 30, No. 4Biological Psychiatry, Vol. 67, No. 2Neuropsychoanalysis, Vol. 11, No. 1Psychiatry Investigation, Vol. 6, No. 1Children of Depressed Mothers 1 Year After the Initiation of Maternal Treatment: Findings From the STAR*D-Child StudyDaniel J. Pilowsky, M.D., M.P.H.Priya Wickramaratne, Ph.D.Ardesheer Talati, Ph.D.Min Tang, M.A.Carroll W. Hughes, Ph.D.Judy Garber, Ph.D.Erin Malloy, M.D.Cheryl King, Ph.D.Gabrielle Cerda, M.D.A. Bela Sood, M.D.Jonathan E. Alpert, M.D., Ph.D.Madhukar H. Trivedi, M.D.Maurizio Fava, M.D.A. John Rush, M.D.Stephen Wisniewski, Ph.D.Myrna M. Weissman, Ph.D.1 September 2008 | American Journal of Psychiatry, Vol. 165, No. 9Human Psychopharmacology: Clinical and Experimental, Vol. 23, No. 8Statistics in Medicine, Vol. 27, No. 19Annals of Behavioral Medicine, Vol. 35, No. 3The American Journal of Medicine, Vol. 121, No. 8Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 32, No. 8CNS Spectrums, Vol. 13, No. S8Journal of Psychiatric Research, Vol. 41, No. 3-4Neurotherapeutics, Vol. 4, No. 1JNCI Journal of the National Cancer Institute, Vol. 99, No. 21Psychomotor Slowing as a Predictor of Fluoxetine Nonresponse in Depressed OutpatientsBonnie P. Taylor, Ph.D., Gerard E. Bruder, Ph.D., Jonathan W. Stewart, M.D., Patrick J. McGrath, M.D., Jeffrey Halperin, Ph.D., Howard Ehrlichman, Ph.D., and Frederic M. Quitkin, M.D.1 January 2006 | American Journal of Psychiatry, Vol. 163, No. 1Biological Psychiatry, Vol. 59, No. 3Improving Treatment of Depression in the ElderlyJournal of Clinical Psychopharmacology, Vol. 25, No. 4An experimental design for the development of adaptive treatment strategies7 December 2004 | Statistics in Medicine, Vol. 24, No. 10The Case for Practical Clinical Trials in PsychiatryJohn S. March, M.D., M.P.H., Susan G. Silva, Ph.D., Scott Compton, Ph.D., Mark Shapiro, M.A., Robert Califf, M.D., and Ranga Krishnan, M.D.1 May 2005 | American Journal of Psychiatry, Vol. 162, No. 5Treatment of Refractory Depression29 January 2008Drug Development Research, Vol. 65, No. 4Journal of Affective Disorders, Vol. 87, No. 2-3A Systematic Review of Antidepressant Placebo-Controlled Trials for Geriatric Depression: Limitations of Current Data and Directions for the Future1 September 2004 | Neuropsychopharmacology, Vol. 29, No. 12Current perspectives in the management of treatment-resistant depression1 April 2022 | Dialogues in Clinical Neuroscience, Vol. 6, No. 1Depression and Anxiety, Vol. 19, No. 1, Vol. 250CNS Spectrums, Vol. 9, No. 11Expert Opinion on Pharmacotherapy, Vol. 4, No. 7 Volume 160Issue 2 February 2003Pages 237-237 Metrics PDF download History Published online 1 February 2003 Published in print 1 February 2003
Publication Year: 2003
Publication Date: 2003-02-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 124
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot